Market Cap 9.82M
Revenue (ttm) 17.44M
Net Income (ttm) -21.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -121.39%
Debt to Equity Ratio -5.69
Volume 138,100
Avg Vol 247,480
Day's Range N/A - N/A
Shares Out 13.71M
Stochastic %K 20%
Beta 6.25
Analysts Sell
Price Target $2.42

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children....

Industry: Medical Devices
Sector: Healthcare
Phone: 844 672 4357
Address:
7921 Southpark Plaza, Suite 210, Littleton, United States
Giovannirs3
Giovannirs3 May. 16 at 12:13 AM
$VVOS 👍👍
0 · Reply
Giovannirs3
Giovannirs3 May. 16 at 12:13 AM
$VVOS 🤣
0 · Reply
stockpicker12e
stockpicker12e May. 15 at 11:49 PM
$VVOS these shorts and negatives like loopi are like mosquitos. they only only live a short time
0 · Reply
golfguy42360
golfguy42360 May. 15 at 10:53 PM
$VVOS Kirk is a fucking joke of a CEO.
0 · Reply
Loopi
Loopi May. 15 at 10:46 PM
$VVOS see you at $0.42 very very soon🤣🫵 still optimistic?? okay 🤣🫵🔻🛑🛑
0 · Reply
PrimeZoneNews
PrimeZoneNews May. 15 at 9:52 PM
$VVOS Historically, Vivos Therapeutics’ NT 10-Q filings focused solely on revenue growth without mentioning gross profit. Last month, the company reported a gross profit increase of approximately 60%. For the first time, in the quarter ended March 31, 2026, the company now expects both revenue and gross profit to increase, with gross profit projected at approximately 100% and revenue at 70%, respectively. This progression not only shows strong business growth and demand but also a significant improvement in profitability and operational efficiency, further reinforcing investor confidence in the company’s financial performance.
1 · Reply
fibtrader99
fibtrader99 May. 15 at 9:47 PM
$VVOS backing into numbers based on taking the 70% Rev, 100% GP and 70% SG&A numbers at exact values (could differ slightly) above Q125 numbers, I'm looking around -.41 EPS and Rev of 6.29MM all else staying the same. Beats on both TradingView estimates of -.435 EPS and 4.35MM Rev. GP rising more than revenues at least signals margin growth from SCN, which is a welcome and expected sign. How other OpEx comes in and depreciation, controlling interests, etc. will be telling. Looks like a slight beat, but we will see. Breakdown of expenses and margins will be helpful and any other partnership/expansion news. A beat on both with oversold conditions points to closing the gap on the chart around 1.3 over the coming weeks, but rising bond yields are shaping a tough macro environment, especially for rate sensitive nano cap names like this. Hope we get some relief next week, excited to hear an update nonetheless.
2 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 👇
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 🌞🌞🌞🤣🤣🤗🤗🤗
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 👆🫡👍
0 · Reply
Latest News on VVOS
Vivos Therapeutics Earnings Call Transcript: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 4 weeks ago

Vivos Therapeutics Earnings Call Transcript: Q4 2025


Vivos Therapeutics Reports Full Year 2025 Financial Results

Apr 15, 2026, 4:20 PM EDT - 4 weeks ago

Vivos Therapeutics Reports Full Year 2025 Financial Results


Vivos Therapeutics Transcript: Fireside Chat

Dec 16, 2025, 11:00 AM EST - 5 months ago

Vivos Therapeutics Transcript: Fireside Chat


Vivos Therapeutics opens sleep center in Auburn Hills, Michigan

2025-12-16T13:50:29.000Z - 5 months ago

Vivos Therapeutics opens sleep center in Auburn Hills, Michigan


Vivos Therapeutics Earnings Call Transcript: Q3 2025

Nov 19, 2025, 5:00 PM EST - 6 months ago

Vivos Therapeutics Earnings Call Transcript: Q3 2025


Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

2025-11-19T21:30:18.000Z - 6 months ago

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)


Vivos Therapeutics initiated with a Buy at H.C. Wainwright

2025-11-17T11:15:44.000Z - 6 months ago

Vivos Therapeutics initiated with a Buy at H.C. Wainwright


Vivos Therapeutics Earnings Call Transcript: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 9 months ago

Vivos Therapeutics Earnings Call Transcript: Q2 2025


Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP

2025-07-30T12:50:50.000Z - 10 months ago

Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP


Vivos Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q1 2025


Vivos Therapeutics Earnings Call Transcript: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q4 2024


Vivos Therapeutics Transcript: Fireside Chat

Feb 18, 2025, 12:00 PM EST - 1 year ago

Vivos Therapeutics Transcript: Fireside Chat


Vivos Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q3 2024


Vivos Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q2 2024


Vivos Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q1 2024


Vivos Therapeutics Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q4 2023


Vivos Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q3 2023


Vivos Therapeutics Closes $4 Million Private Placement

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement


Vivos Therapeutics Announces Reverse Stock Split

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Reverse Stock Split


Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine


Vivos Therapeutics Earnings Call Transcript: Q2 2023

Aug 16, 2023, 6:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q2 2023


Giovannirs3
Giovannirs3 May. 16 at 12:13 AM
$VVOS 👍👍
0 · Reply
Giovannirs3
Giovannirs3 May. 16 at 12:13 AM
$VVOS 🤣
0 · Reply
stockpicker12e
stockpicker12e May. 15 at 11:49 PM
$VVOS these shorts and negatives like loopi are like mosquitos. they only only live a short time
0 · Reply
golfguy42360
golfguy42360 May. 15 at 10:53 PM
$VVOS Kirk is a fucking joke of a CEO.
0 · Reply
Loopi
Loopi May. 15 at 10:46 PM
$VVOS see you at $0.42 very very soon🤣🫵 still optimistic?? okay 🤣🫵🔻🛑🛑
0 · Reply
PrimeZoneNews
PrimeZoneNews May. 15 at 9:52 PM
$VVOS Historically, Vivos Therapeutics’ NT 10-Q filings focused solely on revenue growth without mentioning gross profit. Last month, the company reported a gross profit increase of approximately 60%. For the first time, in the quarter ended March 31, 2026, the company now expects both revenue and gross profit to increase, with gross profit projected at approximately 100% and revenue at 70%, respectively. This progression not only shows strong business growth and demand but also a significant improvement in profitability and operational efficiency, further reinforcing investor confidence in the company’s financial performance.
1 · Reply
fibtrader99
fibtrader99 May. 15 at 9:47 PM
$VVOS backing into numbers based on taking the 70% Rev, 100% GP and 70% SG&A numbers at exact values (could differ slightly) above Q125 numbers, I'm looking around -.41 EPS and Rev of 6.29MM all else staying the same. Beats on both TradingView estimates of -.435 EPS and 4.35MM Rev. GP rising more than revenues at least signals margin growth from SCN, which is a welcome and expected sign. How other OpEx comes in and depreciation, controlling interests, etc. will be telling. Looks like a slight beat, but we will see. Breakdown of expenses and margins will be helpful and any other partnership/expansion news. A beat on both with oversold conditions points to closing the gap on the chart around 1.3 over the coming weeks, but rising bond yields are shaping a tough macro environment, especially for rate sensitive nano cap names like this. Hope we get some relief next week, excited to hear an update nonetheless.
2 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 👇
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 🌞🌞🌞🤣🤣🤗🤗🤗
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:10 PM
$VVOS 👆🫡👍
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:09 PM
$VVOS ➖️💯
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 9:09 PM
$VVOS 🤣🤣🤣🤣🤣🤗
0 · Reply
Loopi
Loopi May. 15 at 8:53 PM
$VVOS late submission report again 🤣🫵🫵🫵🚨🛑🛑 Will destroy investors soon 🔜
0 · Reply
kemsma62
kemsma62 May. 15 at 8:49 PM
$VVOS Since the quarterly report for the period ended March 31, 2026 was due on May 15, 2026, the extended filing deadline would be approximately May 20, 2026!
0 · Reply
Giovannirs3
Giovannirs3 May. 15 at 8:42 PM
$VVOS ➖️💯
0 · Reply
PrimeZoneNews
PrimeZoneNews May. 15 at 8:14 PM
$VVOS NT-10Q Vivos Therapeutics, Inc. (the “Company”) expects to report that its revenue and gross profit increased by approximately 70% and 100%, respectively, for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025. The primary cause was due to an increase in sales of Company products and services to patients that resulted from the Company’s 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”), as well as SCN’s legacy diagnostic services that the Company did not have in the prior year quarter.
0 · Reply
GamblerDan
GamblerDan May. 15 at 8:12 PM
0 · Reply
GamblerDan
GamblerDan May. 15 at 8:09 PM
$VVOS Here’s the late filing notice. Fuck you Kirk! https://www.sec.gov/Archives/edgar/data/1716166/000149315226023733/formnt10-q.htm
0 · Reply
fibtrader99
fibtrader99 May. 15 at 8:02 PM
$VVOS New low on weekly RSI of 26.14, Daily oversold as well. Earnings next week
0 · Reply
Loopi
Loopi May. 15 at 7:53 PM
$VVOS Next week $0.42 if not delisting 😭🫵🛑🔻🔻🔻🔻
0 · Reply
Loopi
Loopi May. 15 at 7:47 PM
$VVOS hahaha I told you new lows coming 😭🫵🫵🫵🫵🔻🔻🔻🚨 Dead stock never stop 🛑
0 · Reply
stockpicker12e
stockpicker12e May. 15 at 7:29 PM
$VVOS going to 100 dollars
3 · Reply